Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12117634 | 0.93 | HDAC1 (0.53) | HDAC1MKNK1MKNK2ABCB1HDAC3 | |
| SCHEMBL1316473 | 0.91 | HDAC1 (0.51) | HDAC1HDAC3HDAC2 | |
| SCHEMBL12117593 | 0.90 | MKNK1 (0.51) | HDAC1MKNK1MKNK2ABCB1HDAC3 | |
| SCHEMBL12117635 | 0.89 | LMNA (0.48) | HDAC1MKNK1MKNK2ABCB1HDAC3 | |
| SCHEMBL12118144 | 0.87 | HDAC1 (0.53) | HDAC1ABCB1HDAC3HDAC2ABCC1 | |
| SCHEMBL1316073 | 0.85 | HDAC1 (0.48) | HDAC1HDAC2CYP2C9 | |
| SCHEMBL12117591 | 0.85 | HDAC1 (0.60) | HDAC1MKNK1MKNK2ABCB1HDAC3 | |
| SCHEMBL1318330 | 0.84 | LRRK2 (0.52) | HDAC1MKNK1MKNK2 | |
| SCHEMBL12117760 | 0.84 | HDAC1 (0.44) | HDAC1MKNK1MKNK2ABCB1ABCC1 | |
| SCHEMBL1318945 | 0.84 | HDAC1 (0.59) | HDAC1MKNK1MKNK2ABCB1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| CN-102333757-A | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | HDAC1 73/4885MKNK1 3237/4885MKNK2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.